Background: Chemotherapy-induced interstitial lung disease (ILD) in colorectal cancer (CRC) patients is rarely reported, but its clinical features remain to be clarified. Results: Of 734 patients, 11 patients developed ILD (1.5%) and 4 of those patients died (0.54%). Of the 11 patients, 10 showed pulmonary shadows other than lung metastases before chemotherapy. ILD developed during FOLFOX in six patients, at 137 days after completion of FOLFOX in one patient, during oxaliplatin interruption of FOLFOX in one patient and during FOLFIRI in the remaining three patients. FOLFOX had been administered at some point for all ILD patients, with a median of 10 cycles (range 2-17 cycles) and a median dose of administered oxaliplatin of 850 mg/m 2 (range 170-1445 mg/m 2 ).
introduction
Chemotherapy for colorectal cancer (CRC) has recently undergone substantial development, including the application of effective new drugs such as irinotecan, oxaliplatin, bevacizumab and cetuximab. Standard first-line treatments for CRC comprise oxaliplatin plus infusional 5-fluorouracil (5-FU) and leucovorin (FOLFOX) or irinotecan plus infusional 5-FU and leucovorin (FOLFIRI) [1] [2] [3] [4] , alone or combined with bevacizumab [5] [6] [7] . Moreover, the FOLFOX regimen has shown efficacy as adjuvant chemotherapy for colon cancer [8] .
Chemotherapy-induced interstitial lung disease (ILD) is rarely observed but can cause respiratory failure. Although few case reports have described ILD following FOLFOX or FOLFIRI therapy, rapid progression resulting in death by respiratory failure can occur when this pathology arises [9] [10] [11] [12] [13] [14] [15] [16] . Most CRC clinical trials have not reported any incidence of pulmonary toxicity and, to the best of our knowledge, no systemic reviews to date have described ILD associated with FOLFOX or FOLFIRI for CRC. The present study therefore focused on cases of ILD associated with FOLFOX or FOLFIRI in order to clarify the clinical features.
patients and methods patients
Using a computerized database, we identified 734 patients with CRC treated using FOLFOX or FOLFIRI from April 2005 to December 2008 at the National Cancer Center Hospital East. Among these, 11 patients clinically diagnosed with ILD according to the criteria described below were enrolled in the present study. Written general consent that included research uses of clinical data was obtained from all patients. Data were retrospectively collected. The study was carried out in accordance with the Declaration of Helsinki and Japanese ethical guidelines for epidemiological research. We obtained an institutional review board (IRB) waiver from the IRB chairperson to conduct this study. 
definitions
ILD was diagnosed when all the following criteria were met: observation of interstitial infiltrates or fibrosis on chest computed tomography (CT), lack of response to antibacterial and antifungal therapies and exclusion of other pulmonary diseases on the basis of consultation with an expert. Brinkman index (BI) was determined as the number of cigarettes smoked daily multiplied by the number of years since starting smoking [19] . Preexisting pulmonary shadows were assessed retrospectively using chest CT taken before chemotherapy. characteristics and clinical course in ILD patients ILD occurred in 11 of the 734 patients (1.5%). While none of the 11 patients had infectious signs, the chest CTs of all patients revealed interstitial infiltrations or fibrosis. Results of sputum cultures carried out in 6 of the 11 patients were negative. Empirical administration of antibacterial and antifungal drugs to 10 patients was ineffective in all cases. One patient who was not treated with antibacterial therapy showed a high serum KL-6 level; however, this was improved by interruption of chemotherapy alone. Histological examination was carried out in two patients; results showed pulmonary fibrosis at autopsy (case 1) and nonspecific inflammation at transbronchial lung biopsy (case 11). Malignant cells and bacteria were not observed in either histological sample.
The characteristics of patients with ILD are provided in Table 2 . All patients with ILD were men, and 10 of the 11 patients were heavy smokers. Ten patients showed pulmonary shadows other than lung metastases before chemotherapy. Nine of the 11 patients had rectal cancer, and 8 showed lung metastases. All patients underwent laparotomy, and primary cancer was resected in all except case 2. Main initial symptom at the time of ILD onset was cough in five patients (45.5%), fever in five patients (45.5%) and dyspnea in four patients (36.4%). Allergic reaction to chemotherapy had occurred in one patient (case 4), as a grade 1 reaction to oxaliplatin. Elevated serum KL-6 levels ( ‡500 U/ml) were observed in nine patients (81.8%). Clinical courses of ILD patients are shown in Table 3 . ILD developed during FOLFOX therapy in six patients, on day 137 after completion of FOLFOX in one patient (case 7) and during oxaliplatin interruption due to neurotoxicity in one patient (case 11) who had been treated with FOLFOX plus bevacizumab. In case 7 with liver metastases, the primary tumor was surgically removed and five cycles of FOLFOX were administered as neoadjuvant chemotherapy against liver metastasis. No adjuvant chemotherapy was carried out after curative resection of hepatic metastasis as slight progression of hepatic metastasis was observed after neoadjuvant FOLFOX therapy. ILD developed on day 87 after hepatectomy. In case 11, only infusional 5-FU and leucovorin (sLV5FU2) plus bevacizumab were continued after interruption of oxaliplatin due to sensory neuropathy. The remaining three patients developed ILD during FOLFIRI, including one patient with concurrent bevacizumab therapy.
FOLFOX had been administered in all ILD patients. In terms of ILD onset, median number of cycles of FOLFOX therapy was 10 cycles (range 2-17 cycles) and median dose of oxaliplatin administered was 850 mg/m 2 (range 170-1445 mg/m 2 ). Median duration from last FOLFOX to the ILD-related episode was 20 days (range 0-179 days), and median duration from the episode to the onset of ILD treatment was 10.5 days (range 0-21 days).
Steroid pulse therapy was carried out for 10 patients, excluding 1 patient who underwent drug interruption. Of the 11 patients with ILD, 4 patients (36.4%) died despite intensive therapy. Two patients showed grade 4 pneumonitis at the time of ILD diagnosis and died of respiratory failure within 1 month of diagnosis (cases 1 and 3). Of the other two patients who died after >1 month, one died of pulmonary embolism (case 9) and the other died of respiratory failure (case 11). Of the seven patients who achieved improvement with steroid pulse therapy, five patients subsequently received other chemotherapy regimens. In case 10, ILD occurred after 12 cycles of FOLFOX and 6 cycles of FOLFIRI plus bevacizumab; however, following ILD treatment, FOLFIRI therapy was continued without ILD recurrence.
comparison between the improved and the dead patients A comparison of the 7 improved patients with the 4 dead patients among the 11 patients with ILD is shown in Table 4 . No significant differences in characteristics were identified, possibly due to the small sample size. Median BI was 700 (range 0-1000) in the improved patients and 1085 (range 380-1380) in the dead patients. Pneumonitis grade at the time of diagnosis tended to be higher in the dead patients. Median duration from last dose of any chemotherapy to the ILD-related episode was 8 days (range 0-137 days) in the improved patients and 1.5 days (range 0-10 days) in the dead patients. Median duration from the episode to the start of ILD treatment was 8.5 days (range 0-14 days) in the improved patients and 13 days (range 5-21 days) in the dead patients.
We analyzed the relationship between FOLFOX and ILD as all ILD patients in this study had received FOLFOX at some stage. Median number of cycles of FOLFOX therapy and median dose of oxaliplatin administered were 6 cycles (range 2-17 cycles) and 510 mg/m 2 (range 170-1445 mg/m 2 ) in the improved patients and 10.5 cycles (range 9-13 cycles) and 892.5 mg/m 2 (range 745-1045 mg/m 2 ) in the dead patients, respectively. Median duration from last dose of oxaliplatin to 
discussion
To our knowledge, this study represents the first systemic analysis of the incidence of ILD induced by standard chemotherapy (FOLFOX or FOLFIRI) for CRC, with detailed clinical outcomes. As the incidence of ILD is low, evaluating detailed pulmonary toxicity induced by chemotherapy in a prospective clinical trial is difficult. In fact, ILD has not been described in any articles published to date regarding clinical trials for CRC. We thus retrospectively evaluated the clinical features of ILD after treatment with FOLFOX or FOLFIRI for advanced CRC. ILD developed in 11 of the 734 patients (1.5%) identified for the present study, including 4 patients who died (0.54%). In a previous study, ILD reportedly developed with gefitinib treatment of non-small-cell lung cancer in 1%-5% of patients, proving fatal in about one-third of these [20] [21] [22] . These results indicate that ILD constitutes a critical complication in chemotherapy for CRC, as well as non-small-cell lung cancer. Median duration to the onset of ILD following gefitinib was reportedly 24-42 days [20] ; however, time to onset in the present study was much longer than that reported for gefitinib. These results indicate that ILD in the present study might have involved a different mechanism from that associated with gefitinib and may instead resemble ILD induced by cytotoxic drugs such as bleomycin and mitomycin, which generally induce ILD >2 months after therapy [10] .
Identifying the culprit agent is challenging because multiple antineoplastic agents are usually used for CRC. However, causes may be surmised on the basis of clinical course and previous reports. To the best of our knowledge, no cases of ILD induced by 5-FU or leucovorin have been reported unless in combination with other antineoplastic agent or irradiation. Irinotecan alone reportedly produced a 9%-13% incidence of pulmonary toxicity in the initial Japanese study for non-smallcell lung cancer and small-cell lung cancer [23, 24] . However, the exact contribution of irinotecan to pulmonary toxicity is unknown as this disease may be substantially influenced by primary lung cancer and the quality of old clinical trial data cannot be confirmed. In fact, the frequency of irinotecaninduced ILD was only 0.8% in a phase II trial for CRC patients [25] and 0.9% in Japanese post-marketing surveillance (J-PMS) of irinotecan for 15 385 patients.
In contrast, several case reports of oxaliplatin-induced ILD have already been published. Details of those cases are shown in Table 5 [11] [12] [13] [14] [15] [16] [26] [27] [28] . Furthermore, among the previous reports of ILD associated with irinotecan, oxaliplatin was administered before irinotecan application [29] . An interesting finding in the present study was that FOLFOX had been administered to all ILD patients. Moreover, oxaliplatin may be associated with late development of ILD, which arose on day 137 after completion of FOLFOX in case 7 and on day 108 after discontinuation of oxaliplatin in case 11. In both cases, no specific drugs that might have induced ILD had been used. Although we cannot exclude the potential influence of anesthesia and postoperative drugs in case 7, their involvement seems unlikely. Medical reviews of oxaliplatin by the USA Food and Drug administration (FDA) [30, 31] and J-PMS of oxaliplatin and bevacizumab safety provide information on the incidence and severity of ILD (Table 6 ). Mentions of 'pneumonitis', 'interstitial pneumonia' and 'pulmonary fibrosis' therein were extracted as ILD and the incidence of ILD in the present study (1.5%) is within the range described in these reports (0%-4.2%). The FDA reviews revealed that the incidence of pulmonary symptoms such as cough, hypoxia and dyspnea was increased in oxaliplatin-containing regimens. Of the six patients with ILD in the J-PMS-bevacizumab report, five underwent combined FOLFOX therapy and one combined FOLFIRI. ILD in the present study could have been induced by either oxaliplatin or irinotecan; however, these results indicate that oxaliplatin may have a greater effect on ILD onset. In the present study, oxaliplatin was administered for a median of 10 cycles at a median dose of 850 mg/m 2 before onset of ILD.
A median of six cycles of oxaliplatin had been administered in the previous cases reported in Table 5 . Notably, 10 of 11 patients with ILD showed pulmonary shadows before chemotherapy, as well as in previous cases VIII-X in Table 5 . The present results support previous suggestions that preexisting pulmonary disorders represent a risk factor for gefitinib-induced ILD [21, 22] . Furthermore, a recent report described three patients with preexisting ILD who developed symptomatic and radiological worsening of ILD associated with oxaliplatin [12] . Careful follow-up is thus necessary when patients with preexisting pulmonary damage receive oxaliplatin. Moreover, 7 of 11 patients had lung I-XII, colorectal cancer; XIII, XIV, gastric cancer; M, male; F, female; BI, Brinkman index; R, rectum; S, sigmoid colon; Right, right colon; T, transverse colon; R Hemi, right hemicolectomy; AR, anterior resection; Sigm, sigmoidectomy; GC, gastric cancer; Subtotal, subtotal gastrectomy; PSL, prednisolone; -, not described; L-OHP, oxaliplatin; CPT-11, irinotecan; LV, leucovorin. 
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metastases in the present study and this type of metastasis may thus represent a risk factor for ILD similar to that represented by preexisting pulmonary disorders. However, this remains hypothetical as frequent chest CTs for lung metastasis may result in a high discovery rate of ILD or radiation-induced ILD. Although no significant patient differences were noted in this study because of the small sample size, factors predictive of response to steroid therapy for ILD were extracted by comparison between improved and dead patients. BI and pneumonitis grade at the time of diagnosis were higher for patients who died than for improved patients. Previous case reports have also indicated similar tendencies, with reported deaths in four of six patients showing pneumonitis of grade 3 or higher but only one of eight patients with grade 2 or less (Table 5 ). Shorter duration between last dosage of chemotherapy and the ILD-related episode also tended to be associated with worse outcomes. Early appearance of symptoms after drug exposure may thus indicate more severe ILD. As expected, duration from the onset of ILD to treatment was shorter in improved patients than in dead patients. Early diagnosis and treatment of ILD are thus crucial. Interruption of the culprit agent and systemic corticosteroid has been widely accepted as therapy for drug-induced ILD though no randomized controlled trial has been done [9] . We recommend that treatments should be selected depending on the severity: follow-up or low-dose corticosteroid for less severe ILD patients and steroid pulse therapy using methylprednisolone for severe ILD patients.
In conclusion, ILD is uncommon but represents a lifethreatening complication. Clinicians need to be aware of the possibility of ILD not only during but also after chemotherapy for CRC. Further investigation is required to clarify risk and prognostic factors for ILD.
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